GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theseus Pharmaceuticals Inc (NAS:THRX) » Definitions » ROIC %
中文

Theseus Pharmaceuticals (Theseus Pharmaceuticals) ROIC % : -207.32% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Theseus Pharmaceuticals ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Theseus Pharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2023 was -207.32%.

As of today (2024-04-25), Theseus Pharmaceuticals's WACC % is 10.40%. Theseus Pharmaceuticals's ROIC % is -278.50% (calculated using TTM income statement data). Theseus Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Theseus Pharmaceuticals ROIC % Historical Data

The historical data trend for Theseus Pharmaceuticals's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theseus Pharmaceuticals ROIC % Chart

Theseus Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22
ROIC %
-2,148.70 -4,953.62 -1,107.39 -367.38

Theseus Pharmaceuticals Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -461.91 -304.79 -340.58 -282.43 -207.32

Competitive Comparison of Theseus Pharmaceuticals's ROIC %

For the Biotechnology subindustry, Theseus Pharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theseus Pharmaceuticals's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theseus Pharmaceuticals's ROIC % distribution charts can be found below:

* The bar in red indicates where Theseus Pharmaceuticals's ROIC % falls into.



Theseus Pharmaceuticals ROIC % Calculation

Theseus Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-54.086 * ( 1 - 0% )/( (4.891 + 24.553)/ 2 )
=-54.086/14.722
=-367.38 %

where

Theseus Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2023 is calculated as:

ROIC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-65.612 * ( 1 - 0% )/( (34.309 + 28.987)/ 2 )
=-65.612/31.648
=-207.32 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theseus Pharmaceuticals  (NAS:THRX) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Theseus Pharmaceuticals's WACC % is 10.40%. Theseus Pharmaceuticals's ROIC % is -278.50% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Theseus Pharmaceuticals ROIC % Related Terms

Thank you for viewing the detailed overview of Theseus Pharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theseus Pharmaceuticals (Theseus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, Cambridge, MA, USA, 02142
Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
Executives
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Foresite Capital Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradford D. Dahms officer: Chief Financial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Timothy P Clackson director, officer: President and CEO C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Steven H Stein director 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Foresite Capital Opportunity Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Opportunity Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
James B. Tananbaum 10 percent owner 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
William Shakespeare officer: See Remarks 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp 10 percent owner 190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Theseus Pharmaceuticals (Theseus Pharmaceuticals) Headlines

From GuruFocus